Roles of arrest-defective protein 1225 and hypoxia-inducible factor 1α in tumor growth and metastasis

Cited 18 time in scopus
Metadata Downloads

Full metadata record

DC FieldValueLanguage
dc.contributor.authorM N Lee-
dc.contributor.authorS N Lee-
dc.contributor.authorS H Kim-
dc.contributor.authorB Kim-
dc.contributor.authorB K Jung-
dc.contributor.authorJ H Seo-
dc.contributor.authorJ H Park-
dc.contributor.authorJ H Choi-
dc.contributor.authorS H Yim-
dc.contributor.authorM R Lee-
dc.contributor.authorJong Gil Park-
dc.contributor.authorJ Y Yoo-
dc.contributor.authorJ H Kim-
dc.contributor.authorS T Lee-
dc.contributor.authorHwan Mook Kim-
dc.contributor.authorS Ryeom-
dc.contributor.authorK W Kim-
dc.contributor.authorG T Oh-
dc.date.accessioned2017-04-19T09:18:20Z-
dc.date.available2017-04-19T09:18:20Z-
dc.date.issued2010-
dc.identifier.issn0027-8874-
dc.identifier.uri10.1093/jnci/djq026ko
dc.identifier.urihttps://oak.kribb.re.kr/handle/201005/9485-
dc.description.abstractBackground Vascular endothelial growth factor A (VEGFA), a critical mediator of tumor angiogenesis, is a well-characterized target of hypoxia-inducible factor 1 (HIF-1). Murine arrest-defective protein 1A (mARD1A225) acetylates HIF-1α, triggering its degradation, and thus may play a role in decreased expression of VEGFA.Methods We generated ApcMin/+/mARD1A225 transgenic mice and quantified growth of intestinal polyps. Human gastric MKN74 and murine melanoma B16F10 cells overexpressing mARD1A225 were injected into mice, and tumor growth and metastasis were measured. VEGFA expression and microvessel density in tumors were assessed using immunohistochemistry. To evaluate the role of mARD1A 225 acetylation of Lys532 in HIF-1α, we injected B16F10-mARD1A225 cell lines stably expressing mutant HIF-1α/K532R into mice and measured metastasis. All statistical tests were two-sided, and P values less than. 05 were considered statistically significant.Results ApcMin/+/mARD1A225 transgenic mice (n = 25) had statistically significantly fewer intestinal polyps than Apc Min/+ mice (n = 21) (number of intestinal polyps per mouse: Apc Min/+ mice vs ApcMin/+/mARD1A225 transgenic mice, mean = 83.4 vs 38.0 polyps, difference = 45.4 polyps, 95% confidence interval [CI] = 41.8 to 48.6; P <. 001). The growth and metastases of transplanted tumors were also statistically significantly reduced in mice injected with mARD1A225-overexpressing cells than in mice injected with control cells (P <. 01). Moreover, overexpression of mARD1A 225 decreased VEGFA expression and microvessel density in tumor xenografts (P <. 04) and ApcMin/+ intestinal polyps (P =. 001). Mutation of lysine 532 of HIF-1α in B16F10-mARD1A225 cells prevented HIF-1α degradation and inhibited the antimetastatic effect of mARD1A225 (P <. 001).Conclusion mARD1A225 may be a novel upstream target that blocks VEGFA expression and tumor-related angiogenesis.-
dc.publisherOxford Univ Press-
dc.titleRoles of arrest-defective protein 1225 and hypoxia-inducible factor 1α in tumor growth and metastasis-
dc.title.alternativeRoles of arrest-defective protein 1225 and hypoxia-inducible factor 1α in tumor growth and metastasis-
dc.typeArticle-
dc.citation.titleJournal of National Cancer Institute-
dc.citation.number6-
dc.citation.endPage442-
dc.citation.startPage426-
dc.citation.volume102-
dc.contributor.affiliatedAuthorJong Gil Park-
dc.contributor.affiliatedAuthorHwan Mook Kim-
dc.contributor.alternativeName이미니-
dc.contributor.alternativeName이시내-
dc.contributor.alternativeName김세희-
dc.contributor.alternativeName김보라-
dc.contributor.alternativeName정보경-
dc.contributor.alternativeName서지해-
dc.contributor.alternativeName박지현-
dc.contributor.alternativeName최재훈-
dc.contributor.alternativeName임선희-
dc.contributor.alternativeName이미란-
dc.contributor.alternativeName박종길-
dc.contributor.alternativeName유지영-
dc.contributor.alternativeName김정훈-
dc.contributor.alternativeName이승택-
dc.contributor.alternativeName김환묵-
dc.contributor.alternativeNameRyeom-
dc.contributor.alternativeName김규원-
dc.contributor.alternativeName오구택-
dc.identifier.bibliographicCitationJournal of National Cancer Institute, vol. 102, no. 6, pp. 426-442-
dc.identifier.doi10.1093/jnci/djq026-
dc.description.journalClassY-
Appears in Collections:
Division of Biomedical Research > Biotherapeutics Translational Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.